Please use this identifier to cite or link to this item: https://doi.org/10.2174/157489208786242278
DC FieldValue
dc.titleTargeting heparan sulfate proteoglycans in breast cancer treatment
dc.contributor.authorKoo, C.-Y.
dc.contributor.authorSen, Y.-P.
dc.contributor.authorBay, B.-H.
dc.contributor.authorYip, G.W.
dc.date.accessioned2015-09-07T09:55:48Z
dc.date.available2015-09-07T09:55:48Z
dc.date.issued2008
dc.identifier.citationKoo, C.-Y., Sen, Y.-P., Bay, B.-H., Yip, G.W. (2008). Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Patents on Anti-Cancer Drug Discovery 3 (3) : 151-158. ScholarBank@NUS Repository. https://doi.org/10.2174/157489208786242278
dc.identifier.issn15748928
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/120696
dc.description.abstractBreast carcinoma is one of the leading causes of mortality among female cancers globally. Heparan sulfate proteoglycans, found predominantly on cell surfaces and in the extracellular matrix, are known to regulate breast cancer cellular behavior. Many studies have shown that these molecules serve as potential biomarkers for breast cancer. In addition, they have aberrant expression patterns and participate in various molecular signaling pathways in tumor-progression. There is substantial interest in targeting heparan sulfate proteoglycans for cancer treatment, which needs to be tailored according to the roles that each proteoglycan plays in cancer biology. Current clinical trials using phosphomannopentaose sulfate, a heparan sulfate mimic, and various forms of heparin have produced promising results in breast cancer patients. Besides heparan sulfate chains, novel therapeutic agents could potentially be developed to regulate the proteoglycan core proteins as well as enzymes that modify heparan sulfation patterns. This review discusses the current use and future prospective applications of heparan sulfate proteoglycans, which have been recently patented, as therapeutic targets in breast cancer treatment. © 2008 Bentham Science Publishers Ltd.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.2174/157489208786242278
dc.sourceScopus
dc.subjectAngiogenesis
dc.subjectBreast cancer
dc.subjectEndosulfatase
dc.subjectGlycosaminoglycans
dc.subjectGlypican
dc.subjectHeparan sulfate
dc.subjectHeparanase
dc.subjectHeparin
dc.subjectMetastasis
dc.subjectPhosphomannopentaose sulfate
dc.subjectProteoglycans
dc.subjectSyndecan
dc.subjectTreatment
dc.typeReview
dc.contributor.departmentANATOMY
dc.description.doi10.2174/157489208786242278
dc.description.sourcetitleRecent Patents on Anti-Cancer Drug Discovery
dc.description.volume3
dc.description.issue3
dc.description.page151-158
dc.identifier.isiut000260530500001
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

22
checked on Apr 13, 2021

WEB OF SCIENCETM
Citations

21
checked on Apr 5, 2021

Page view(s)

79
checked on Apr 10, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.